CYP2E1 and metabolic dysfunction-associated steatotic liver disease: Unfortunately, unlike the painkiller APAP, no investigations have been carried out in experimental NAFLD models in order to confirm that higher hepatic CYP2E1 activity is responsible for increased halothane hepatotoxicity in obesity.